Repligen, BioLife receive US approval, await stockholder adoption
Repligen and BioLife Solutions received US antitrust approval for their $1.5 billion merger on Sept. 3 with the expiration of their Hart-Scott-Rodino Act waiting period.Repligen and BioLife Solutions received US antitrust...To view the full article, register now.
Already a subscriber? Click here to view full article